Novartis AG $NVS Stake Boosted by Transmarket Holdings LP

Transmarket Holdings LP boosted its stake in shares of Novartis AG (NYSE:NVS) by 1,474.3% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 35,075 shares of the company’s stock after purchasing an additional 32,847 shares during the quarter. Novartis accounts for about 2.9% of Transmarket Holdings LP’s holdings, making the stock its 7th biggest position. Transmarket Holdings LP’s holdings in Novartis were worth $5,358,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Arlington Trust Co LLC acquired a new position in shares of Novartis in the fourth quarter worth about $25,000. Archer Investment Corp raised its holdings in shares of Novartis by 93.0% during the first quarter. Archer Investment Corp now owns 166 shares of the company’s stock valued at $25,000 after acquiring an additional 80 shares during the period. CrossGen Wealth LLC acquired a new stake in shares of Novartis during the fourth quarter valued at approximately $28,000. Bank of Jackson Hole Trust lifted its position in shares of Novartis by 425.0% in the 4th quarter. Bank of Jackson Hole Trust now owns 231 shares of the company’s stock valued at $32,000 after acquiring an additional 187 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC purchased a new position in Novartis during the 3rd quarter worth approximately $33,000. 13.12% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis topped Q2 earnings estimates, posting $2.41 per share versus $2.17 expected, while revenue also came in above forecasts. The beat was driven by strong demand for key drugs and lower-than-expected costs. Novartis earnings report
• Positive Sentiment: The company returned to sales growth in Q2 as newer medicines offset generic pressure, with strength in cancer and multiple sclerosis treatments helping support results. Reuters Q2 profit story
• Positive Sentiment: Management reaffirmed full-year 2026 guidance, which suggests confidence that growth from newer products can continue despite headwinds. Zacks earnings recap
• Neutral Sentiment: Investors are also watching upcoming late-stage trial readouts in the second half of the year, which could influence the stock’s longer-term valuation narrative. Reuters pipeline valuation story
• Negative Sentiment: Ongoing generic competition and a sharp drop in Entresto sales remain major headwinds, and investors may worry about pressure on older blockbusters. Invezz Entresto sales drop story

Analyst Upgrades and Downgrades

NVS has been the topic of several recent analyst reports. Weiss Ratings downgraded shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research note on Wednesday, April 29th. Morgan Stanley raised their target price on Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a research report on Thursday, March 26th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $141.20.

Novartis Price Performance

Shares of NVS opened at $153.82 on Wednesday. The business’s 50-day moving average is $151.61 and its 200-day moving average is $151.88. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.85 and a quick ratio of 0.65. The company has a market capitalization of $293.51 billion, a price-to-earnings ratio of 22.04, a P/E/G ratio of 2.58 and a beta of 0.45. Novartis AG has a fifty-two week low of $112.34 and a fifty-two week high of $170.46.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a net margin of 24.87% and a return on equity of 38.82%. The business had revenue of $14.95 billion during the quarter. Equities research analysts expect that Novartis AG will post 8.75 EPS for the current fiscal year.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.